Alx Oncology Holdings (ALXO) Amortization of Deferred Charges (2020 - 2026)

Alx Oncology Holdings has reported Amortization of Deferred Charges for 5 years, with the latest figure at $68000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 1.49% year-over-year to $68000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281000.0 (up 4.85% YoY) and the FY2025 annual result came in at $280000.0, up 5.66% from the prior year.
• Amortization of Deferred Charges retreated to $68000.0 in Q1 2026 per ALXO's latest filing, from $72000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $72000.0 in Q3 2025 and troughed at $61000.0 in Q1 2023.
• A 4-year average of $66384.6 and a median of $66000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2025 and 2026: Amortization of Deferred Charges climbed 9.09% in 2025, then advanced 1.49% in 2026.
• Over 4 years, Amortization of Deferred Charges stood at $64000.0 in 2023, then advanced by 7.81% to $69000.0 in 2024, then climbed by 4.35% to $72000.0 in 2025, then dropped by 5.56% to $68000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $68000.0, $72000.0, and $72000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.